Navigation Links
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Date:5/7/2009

g behavior - in one daily capsule. Qnexa, an investigational drug, is an obesity therapy being developed to address type 2 diabetes as well as weight loss. In phase 2 and phase 3 clinical trials to date, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors. Qnexa is well tolerated, with no drug-related serious adverse events reported to date.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
7. Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
8. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
9. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... Surgeons at The Children,s Hospital of ... the first successful use of a SynCardia temporary Total ... failing Fontan circulation to bridge him to a heart ... the patient received a Fontan circulation procedure to address ... Fontan operation is the final planned palliative operation for ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 413-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE ... Taylor, one of the Company,s funded researchers, will ... on SNS-01, Senesco,s multiple myeloma drug candidate, at ... Cancer Institute (NCI)-European Organization for Research and Treatment ...
... Nov. 12 Ionian Technologies, Inc. and Roche ... based on Ionian,s rapid isothermal nucleic acid amplification ... applications and customers for the technology and will ... exclusive manufacturing rights for these specific opportunities upon ...
Cached Medicine Technology:Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 3
(Date:9/17/2014)... 17, 2014 Altec Products, Inc., a ... today their Gold Sponsorship of the 2014 Epicor Prophet ... annual conference will take place in Dallas, TX at ... and is organized and hosted by the Epicor Prophet ... comprised of members from more than 900 companies in ...
(Date:9/17/2014)... Experienced dress company, Discount-Dress.com, announces that its ... trendy black bridesmaid dresses. Furthermore, the company has recently ... outfits. Readers can view more about the ... is a famous brand of special occasion gowns and ... as revamped old editions, the supplier has set a ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 In a ... San Diego, Dr. William Groff, an expert on the condition ... it. Pearly penile papules , or PPP, is a ... thirties, although other men may be affected as well. The ... the penis. , “While PPP is not a sexually ...
(Date:9/17/2014)... biofilms conjure up images of slippery stones in a ... "bad" biofilms around they even cause pesky dental ... problems a team at the Wyss Institute for ... a robust new platform for designer nanomaterials that could ... textiles, and more. , In short, they want ...
(Date:9/17/2014)... Colo. (PRWEB) September 17, 2014 In ... Sentinel University offers tips to health IT professionals for ... , A recent study by HIMSS shows demand for ... and a candidate’s skill set is the differentiating factor ... that of an IT professional that has clinical workflow ...
Breaking Medicine News(10 mins):Health News:Altec Joins the 2014 Epicor Prophet 21 World Wide User Group Conference as a Gold Sponsor 2Health News:Altec Joins the 2014 Epicor Prophet 21 World Wide User Group Conference as a Gold Sponsor 3Health News:Discount-Dress.com’s Top Designers Are Now Busy Making Its New Black Bridesmaid Dresses 2Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Recruiting bacteria to be technology innovation partners 2Health News:Recruiting bacteria to be technology innovation partners 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 4
... of the nation,s largest Medicaid managed care organizations to implement ... , - The aim of the DailyMed(TM) program is to ... and decrease hospitalizations. , , INDIANAPOLIS, June 24 ... has signed an agreement with Arcadia Resources, Inc. (NYSE Amex: ...
... California to participate in the Foundation,s Orange ... , , NEW YORK, June 24 The Crohn,s & ... six winners from the second annual Celebrating UC Success ... is a program that honors people who have found personal ways ...
... Inc., a developer of innovative therapies in women,s health, ... Coast Service Options, Inc. ("First Coast"), a large regional ... Puerto Rico and the U.S. Virgin Islands, has removed ... incontinence (SUI) from its noncovered services list and will ...
... , EVANSTON, Ill., June 24 SignatureForum, a leading ... its Platinum Physicians List, featuring the highest-rated cosmetic surgeons ... like the Platinum Skin Care Providers group announced last ... of service providers across the United States and Canada. ...
... Many Americans feel that today,s healthcare system is failing ... made it more difficult to afford health insurance. The pivotal ... physical therapist Mitchell Yass, is whether the costs being incurred ... not -- and what healthcare segment seems to be driving ...
... ZixCorp executive offers advice for healthcare businesses to ensure ... Zix Corporation (ZixCorp(R)) (Nasdaq: ZIXI ), ... announced that ZixCorp Vice President and HIPAA subject matter ... amendments to the healthcare privacy and security obligations under ...
Cached Medicine News:Health News:WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety, Efficacy and Compliance for Medicaid Members 2Health News:WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety, Efficacy and Compliance for Medicaid Members 3Health News:WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety, Efficacy and Compliance for Medicaid Members 4Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 2Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 4Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 5Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 2Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 3Health News:SignatureForum Reveals Top-Rated Cosmetic Surgeons in US 2Health News:One Man's Mission to Improve Our Healthcare System and Resolve Chronic Pain 2Health News:Zix Corporation Addresses New HIPAA Regulations 2Health News:Zix Corporation Addresses New HIPAA Regulations 3
For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
... Intended for the quantitative ... serum. Reaction: kinetic, lag phase ... followed by linear phase of ... 340 nm. Linearity: 120 mg/dL ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Medicine Products: